Osimertinib
Brand names: Tagrisso · Active ingredient: Osimertinib
In short: TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test . TAGRISSO is indicated for the treatm
What is Osimertinib used for?
TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test .
TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test .
TAGRISSO is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test .
TAGRISSO in combination with pemetrexed and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test .
TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy .
Osimertinib dosage
TAGRISSO Monotherapy
•Before initiating TAGRISSO monotherapy in patients with cardiac risk factors, conduct cardiac monitoring, including assessment of left ventricular ejection fraction (LVEF) .
•Before initiating TAGRISSO, perform complete blood count with differential .
TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy
•Before initiating TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring in all patients, including assessment of left ventricular ejection fraction (LVEF) .
•Before initiating TAGRISSO, perform complete blood count with differential .
Table 1 below presents the patient selection criteria for treatment with TAGRISSO.
Select patients for treatment with TAGRISSO based on the presence of a mutation as detected by an FDA-approved test.
Indication | Treatment Regimen | Required Mutation | Source for Testing
Adjuvant Treatment of EGFR Mutation-Positive NSCLC | TAGRISSO monotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Tumor
Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC | Following completion of platinum-based chemoradiation therapy, TAGRISSO monotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Tumor
First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC | TAGRISSO monotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Plasma or tumor
First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC
| TAGRISSO in combination with pemetrexed and platinum-based chemotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Plasma or tumor
Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC | TAGRISSO monotherapy | EGFR T790M Mutation | Plasma or tumor
Information on FDA-approved tests for the detection of EGFR mutations is available at http://www.fda.gov/companiondiagnostics.
Recommended Dosage
Table 2 provides the recommended dosage of TAGRISSO by indication. …
How to take Osimertinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Interstitial Lung Disease/Pneumonitis
Inform patients of the risks of severe or fatal ILD, including pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms .
QTc Interval Prolongation
Inform patients of symptoms that may be indicative of significant QTc prolongation including dizziness, lightheadedness, and syncope. Advise patients to report these symptoms and to inform their physician about the use of any heart or blood pressure medications .
Cardiomyopathy
Inform patients that TAGRISSO can cause cardiomyopathy. Advise patients to immediately report any signs or symptoms of heart failure to their healthcare provider .
Keratitis
Advise patients to contact their healthcare provider immediately if they develop eye symptoms (eye inflammation, lacrimation, light sensitivity, eye pain, red eye or changes in vision) .
Erythema Multiforme Major, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis
Inform patients of signs and symptoms that may be indicative of EMM, SJS, or TEN. …
Warnings & precautions
Do not take this medicine if: None.
TAGRISSO can cause severe and fatal ILD/pneumonitis.
Across clinical trials, interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 patients treated with TAGRISSO monotherapy who had not received recent definitive chemoradiation therapy; 0.4% of cases were fatal.
ILD/Pneumonitis with TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy
In the FLAURA2 study, ILD/pneumonitis occurred in 3.3% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 0.4% of cases were fatal.
ILD/Pneumonitis Following Definitive Platinum-based Chemoradiation Therapy
In the LAURA study, following definitive platinum-based chemoradiation therapy, ILD/pneumonitis, including radiation pneumonitis, occurred in 80 of the 143 patients (56%) who received TAGRISSO monotherapy and 28 of the 73 patients (38%) who received placebo. There was one fatal case (0.7%), 3.5% Grade 3, 34% Grade 2, and 18% Grade 1 adverse reactions of ILD/pneumonitis in TAGRISSO-treated patients. For TAGRISSO-treated patients, ILD/pneumonitis led to permanent discontinuation of TAGRISSO in 7% of patients and dosage interruptions of TAGRISSO in 35% of patients. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD/pneumonitis. In the 80 TAGRISSO-treated patients, ILD/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%.
For patients receiving TAGRISSO who have not received recent definitive platinum-based chemoradiation therapy, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening or respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed . …
Osimertinib side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
•Interstitial Lung Disease/Pneumonitis
•QTc Interval Prolongation
•Cardiomyopathy
•Keratitis
•Erythema multiforme, Stevens-Johnson syndrome, and Toxic epidermal necrolysis
•Cutaneous Vasculitis
•Aplastic Anemia
•Myalgia or Myositis with Creatine Phosphokinase Elevation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data in the WARNINGS AND PRECAUTIONS section reflect exposure to TAGRISSO in 1813 patients with EGFR mutation-positive NSCLC who received TAGRISSO monotherapy at the recommended dose of 80 mg orally once daily until disease progression or unacceptable toxicity in four randomized, controlled trials [ADAURA (n=337), FLAURA (n=338), FLAURA2 (monotherapy arm; n=275), and AURA3 (n=279)] , two single arm trials [AURA Extension (n=201) {NCT01802632} and AURA2 (n=210)]{NCT02094261}, and one dose-finding study, AURA1 (n=173). Among 1813 patients who received TAGRISSO monotherapy, 82% were exposed for 6 months or longer and 67% were exposed for greater than one year. …
Drug interactions
Strong CYP3A Inducers
Co-administering TAGRISSO with a strong CYP3A4 inducer decreased the exposure of osimertinib compared to administering TAGRISSO alone . Decreased osimertinib exposure may lead to reduced efficacy.
Avoid co-administering TAGRISSO with strong CYP3A inducers. Increase the TAGRISSO dosage when co-administering with a strong CYP3A4 inducer if concurrent use is unavoidable . No dose adjustments are required when TAGRISSO is used with moderate and/or weak CYP3A inducers.
Co-administering TAGRISSO with a breast cancer resistant protein (BCRP) or P-glycoprotein (P-gp) substrate increased the exposure of the substrate compared to administering it alone . Increased BCRP or P-gp substrate exposure may increase the risk of exposure-related toxicity.
Monitor for adverse reactions of the BCRP or P-gp substrate, unless otherwise instructed in its approved labeling, when co-administered with TAGRISSO.
The effect of co-administering medicinal products known to prolong the QTc interval with TAGRISSO is unknown. When feasible, avoid concomitant administration of drugs known to prolong the QTc interval with known risk of Torsades de pointes. If not feasible to avoid concomitant administration of such drugs, conduct periodic ECG monitoring .
About this medicine
Osimertinib is a kinase inhibitor for oral use. The molecular formula for osimertinib mesylate is C28H33N7O2•CH4O3S, and the molecular weight is 596 g/mol. The chemical name is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt. Osimertinib has the following structural formula (as osimertinib mesylate):
TAGRISSO tablets contain 40 or 80 mg of osimertinib, equivalent to 47.7 and 95.4 mg of osimertinib mesylate, respectively. Inactive ingredients in the tablet core are mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and sodium stearyl fumarate. The tablet coating consists of polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black.
How it works: Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5e81b4a7-b971-45e1-9c31-29cea8c87ce7. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate